New self-amplifying RNA HIV vaccine development
Core-001
This project is developing an RNA-based HIV vaccine designed to protect people at risk for or living with HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11242067 on NIH RePORTER |
What this research studies
This core team makes the vaccine material: self-amplifying RNA that tells cells to make HIV proteins, and a nanostructured lipid carrier to deliver that RNA. They will produce and validate research-grade vaccine batches, test them in cells and animal models to confirm the RNA works and the proteins are made, and share materials with partner labs for antigen testing. The team will also run stability tests and prepare the data needed for later manufacturing under clinical standards and for a future Phase I trial. All of these steps are about preparing a vaccine candidate that could move into human testing if results are promising.
Who could benefit from this research
Good fit: Adults at risk for HIV exposure or people living with HIV could be candidates for later clinical trials once safety in preclinical testing is shown.
Not a fit: People needing immediate treatment for active HIV infection, pregnant people, or children are unlikely to benefit directly from this early-stage, preclinical work.
Why it matters
Potential benefit: If successful, this work could lead to a new HIV vaccine candidate entering human trials and eventually help prevent or control HIV infection.
How similar studies have performed: Related RNA-and-lipid vaccine approaches have shown strong immune responses in animals and mRNA lipid vaccines have succeeded in humans, but self-amplifying RNA for HIV remains early and needs human testing.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Stamatatos, Leonidas — Fred Hutchinson Cancer Center
- Study coordinator: Stamatatos, Leonidas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.